Literature DB >> 12011821

Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children.

Agnès Tran1, Elisabeth Rey, Gérard Pons, Ann Pariente-Khayat, Philippe D'Athis, Valentine Sallerin, Christophe Dupont.   

Abstract

OBJECTIVE: We investigated the pharmacokinetics, pharmacodynamics, and tolerability of lansoprazole in children after single and multiple administrations.
METHODS: Forty children (age range, 18 days-14 years) with gastric acid-related disorders entered an open study and received lansoprazole in a single dose of 17 mg. m(-2) (group A) or in multiple doses (17 mg. m(-2) per day) for 7 to 14 days (group B). Lansoprazole plasma concentrations were measured by HPLC. A 24-hour intragastric pH monitoring assessed the antisecretory effect.
RESULTS: In group A, maximal concentration (C(max)) was 1023 +/- 775 (mg. L(-1))/(17 mg. m(-2)), time to reach C(max) was 1.8 +/- 0.8 hours, elimination half-life was 1.5 +/- 2.0 hours, area under the concentration-time curve from time zero to infinity [AUC(0-infinity)] was 3503 +/- 6025 (mg. L(-1). h)/(17 mg. m(-2)), apparent plasma clearance was 0.57 +/- 0.47 L. h(-1). kg(-1), and apparent volume of distribution was 0.61 +/- 0.36 L. kg(-1). In group B, C(max) was 750 +/- 511 (mg. L(-1))/(17 mg. m(-2)), time to reach C(max) was 1.8 +/- 1.1 hours, elimination half-life was 1.2 +/- 1.1 hours, AUC(0-infinity) was 2351 +/- 3691 (mg. L(-1). h)/(17 mg. m(-2)), apparent plasma clearance was 0.71 +/- 0.50 L. h(-1). kg(-1), and apparent volume of distribution was 0.9 +/- 0.7 L. kg(-1). No influence of age was shown on pharmacokinetic parameters in both groups. However, data suggested that elimination was reduced in neonates and higher in infants than in adults. The values for 24-hour percentage of time at gastric pH <4 and pH <3 were 61% +/- 21% and 51% +/- 21% (group A) and 47% +/- 24% and 37% +/- 21% (group B), respectively. In both groups the antisecretory effect decreased with age, and in group A it was positively correlated to C(max) and AUC(0-infinity). The mean gastrin serum concentration significantly increased (+31%) after 12.6 +/- 1.5 days of treatment.
CONCLUSIONS: Lansoprazole was well tolerated in children. After a single oral dose of 30 mg per 1.73 m(2), there was a trend for the elimination to be higher in infants than in adults and the antisecretory effect appeared to be higher in infants younger than 6 months than in older children and adults.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12011821     DOI: 10.1067/mcp.2002.122472

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  17 in total

1.  Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood.

Authors:  Ersin Gumus; Ozgur Karaca; Melih O Babaoglu; Gökhan Baysoy; Necati Balamtekin; Hulya Demir; Nuray Uslu; Atilla Bozkurt; Aysel Yuce; Umit Yasar
Journal:  Eur J Clin Pharmacol       Date:  2011-11-11       Impact factor: 2.953

2.  Crying in infant GERD: acid or volume? Heartburn or dyspepsia?

Authors:  Susan R Orenstein
Journal:  Curr Gastroenterol Rep       Date:  2008-10

3.  Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease.

Authors:  Brinda K Tammara; Janice E Sullivan; Kim G Adcock; Jaroslaw Kierkus; John Giblin; Natalie Rath; Xu Meng; Mary K Maguire; Gail M Comer; Robert M Ward
Journal:  Clin Pharmacokinet       Date:  2011-08       Impact factor: 6.447

4.  Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients.

Authors:  Géraldine Pettersen; Mohamad-Samer Mouksassi; Yves Théorêt; Line Labbé; Christophe Faure; Bao Nguyen; Catherine Litalien
Journal:  Br J Clin Pharmacol       Date:  2008-10-23       Impact factor: 4.335

Review 5.  Developmental pharmacokinetics in pediatric populations.

Authors:  Hong Lu; Sara Rosenbaum
Journal:  J Pediatr Pharmacol Ther       Date:  2014 Oct-Dec

Review 6.  Current pharmacological management of gastro-esophageal reflux in children: an evidence-based systematic review.

Authors:  Mark P Tighe; Nadeem A Afzal; Amanda Bevan; R Mark Beattie
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

7.  Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment.

Authors:  Benjamin D Gold; James W Freston
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

8.  Age-dependent pharmacokinetics of lansoprazole in neonates and infants.

Authors:  Weijiang Zhang; Michael Kukulka; Galen Witt; Debra Sutkowski-Markmann; Janine North; Stuart Atkinson
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

9.  Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged <1 year.

Authors:  Margaret Springer; Stuart Atkinson; Janine North; Marsha Raanan
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

Review 10.  Lansoprazole: in the management of gastroesophageal reflux disease in children.

Authors:  Lesley J Scott
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.